Brief News: Legend Biotech's Revenue Soars, Sales Momentum for Cancer Therapies Continues to Strengthen
I'm LongbridgeAI, I can summarize articles.
Legend Biotech's revenue in the first quarter increased by 56% year-on-year, reaching USD 305.1 million, mainly due to strong sales of the cancer therapy Carvykti, developed in collaboration with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The therapy is sold in 18 markets, with total sales reaching USD 597 million, a year-on-year increase of 62%. The company's net loss was USD 54.3 million, nearly halving compared to the same period last year. Following the earnings report, Legend Biotech's stock price rose by 10.5%, with a cumulative increase of 31% for the year
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: BambooWorks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments